Medical Costs of CKD in the Medicare Population
Medical Costs of CKD in the Medicare Population
复制标题
DOI：
10.1681/asn.2012040392
复制
发表时间：
2013-09-01
影响因子：
13.6
通讯作者：
Williams, Desmond
中科院分区：
文献类型：
--
作者：
Honeycutt, Amanda A.;Segel, Joel E.;Williams, Desmond
为评估延缓肾病进展的干预措施的经济效益，需要对慢性肾脏病（CKD）不同阶段相关的医疗费用进行估算。我们将美国国家健康与营养检查调查的实验室数据与医疗保险索赔的支出数据相结合，以估算医疗保险计划中可归因于慢性肾脏病1 - 4期的年度费用。患有1期肾病患者的医疗保险费用与零无显著差异。经调整为2010年美元价值后，可归因于慢性肾脏病的每人年度医疗保险费用在2期为1700美元，3期为3500美元，4期为12700美元。我们的研究结果表明，在医疗保险受益人中，即使在慢性肾脏病早期阶段，可归因于该病的医疗费用也是相当可观的；此外，随着疾病严重程度的加重，费用会增加。这些费用估算可能有助于评估预防或延缓慢性肾脏病进展的干预措施的净经济效益。
Estimates of the medical costs associated with different stages of CKD are needed to assess the economic benefits of interventions that slow the progression of kidney disease. We combined laboratory data from the National Health and Nutrition Examination Survey with expenditure data from Medicare claims to estimate the Medicare program's annual costs that were attributable to CKD stage 1-4. The Medicare costs for persons who have stage 1 kidney disease were not significantly different from zero. Per person annual Medicare expenses attributable to CKD were $1700 for stage 2, $3500 for stage 3, and $12,700 for stage 4, adjusted to 2010 dollars. Our findings suggest that the medical costs attributable to CKD are substantial among Medicare beneficiaries, even during the early stages; moreover, costs increase as disease severity worsens. These cost estimates may facilitate the assessment of the net economic benefits of interventions that prevent or slow the progression of CKD.